ENVISION Phase 3 Study

• March 2, 2018
• Clinical Trials

Evaluating the effect of givosiran (ALN-AS1) on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).

Trial Status: Enrolling

Interested in learning more? Please email us at clinicaltrials@alnylam.com

For more info: ClinicalTrials.gov – NCT03338816